Wednesday, February 24, 2021
One dose is enough
J&J vaccine 66 percent effective
In addition to the vaccines against the coronavirus that have already been approved, another preparation could be added in a few days. The Johnson & Johnson vaccine shows good efficacy. Approval in the EU is therefore getting closer and closer.
Johnson & Johnson’s corona vaccine offers strong protection against the coronavirus. That made one new study the US Food and Drug Administration (FDA). The vaccine has an overall effectiveness of 66 percent. The vaccine also shows an effectiveness of 85 percent against severe courses of Covid-19. A vaccinated person has a much lower risk of being hospitalized or of dying from Covid-19.
The Johnson & Johnson vaccine is not yet approved. The results of the FDA should now pave the way for an emergency approval in the USA. The regular approval in the USA was already applied for on February 4th, in the EU on February 15th. An emergency approval from the World Health Organization (WHO) has also been applied for. Such approval from the WHO enables the product to be made available via Covax, a global initiative to provide corona vaccines in poor countries.
The Johnson & Johnson vaccine can be stored for at least three months at normal refrigeration temperatures, which makes it much easier to distribute than the vaccines already approved by Moderna and Pfizer-Biontech. In addition, only one vaccination dose is necessary.
The characteristics are thus similar to the Astrazeneca vaccine, the effectiveness is slightly below that of the vaccine produced by the Swedish-British manufacturer. Klaus Hinterding, Vice President at Astrazeneca Germany, had stated that the vaccine “actually protects more or less 100 percent of the severe course of the disease,” but that it is officially stated to be 70 percent effective.
The use of Astrazeneca’s corona vaccine has met with reservations. Study results had revealed that the preparation only provides minimal protection against mild and moderate diseases after infection with variant B.1.351, which was first discovered in South Africa. In young adults, the effectiveness was therefore 22 percent. As a result, South Africa temporarily stopped its planned vaccinations with the active ingredient and offered them to other African countries.